Earlier today, a joint UN humanitarian assessment team, led by WHO accessed Al-Shifa Hospital in northern Gaza to assess the situation on the ground and conduct a rapid situational analysis, assess medical priorities, and establish logistics options for further missions. The team included public health experts, logistics officers, and security staff from OCHA, UNDSS, UNMAS/UNOPS, UNRWA and WHO.
The mission was deconflicted with the Israel Defense Forces (IDF) to ensure safe passage along the agreed route. However, this was a high-risk operation in an active conflict zone, with heavy fighting ongoing in close proximity to the hospital.
Earlier in the day, the IDF had issued evacuation orders to the remaining 2,500 internally displaced people who had been seeking refuge on the hospital grounds. They, along with a number of mobile patients and hospital staff, had already vacated the facility by the time of the team's arrival.
Due to time limits associated with the security situation, the team was able to spend only one hour inside the hospital, which they described as a “death zone,” and the situation as “desperate.” Signs of shelling and gunfire were evident. The team saw a mass grave at the entrance of the hospital and were told more than 80 people were buried there.
Lack of clean water, fuel, medicines, food and other essential aid over the last six weeks have caused Al-Shifa Hospital—once the largest, most advanced, and best equipped referral hospital in Gaza—to essentially stop functioning as a medical facility. The team observed that due to the security situation, it has been impossible for the staff to carry out effective of waste management in the hospital. Corridors and the hospital grounds were filled with medical and solid waste, increasing the risk of infection. Patients and health staff with whom they spoke were terrified for their safety and health, and pleaded for evacuation. Al-Shifa Hospital can no longer admit patients, with the injured and sick now being directed to the seriously overwhelmed and barely functioning Indonesian Hospital.
There are 25 health workers and 291 patients remaining in Al-Shifa, with several patient deaths having occurred over the previous 2 to 3 days due to the shutting down of medical services. Patients include 32 babies in extremely critical condition, two people in intensive care without ventilation, and 22 dialysis patients whose access to life-saving treatment has been severely compromised. The vast majority of patients are victims of war trauma, including many with complex fractures and amputations, head injuries, burns, chest and abdominal trauma, and 29 patients with serious spinal injuries who are unable to move without medical assistance. Many trauma patients have severely infected wounds due to lack of infection control measures in the hospital and unavailability of antibiotics.
Given the current state of the hospital, which is no longer operational or admitting new patients, the team was requested to evacuate health workers and patients to other facilities. WHO and partners are urgently developing plans for the immediate evacuation of the remaining patients, staff and their families. Over the next 24–72 hours, pending guarantees of safe passage by parties to the conflict, additional missions are being arranged to urgently transport patients from Al-Shifa to Nasser Medical Complex and European Gaza Hospital in the south of Gaza. However, these hospitals are already working beyond capacity, and new referrals from Al-Shifa Hospital will further strain overburdened health staff and resources.
WHO is deeply concerned about the safety and health needs of patients, health workers and internally displaced people sheltering at the few remaining partially functional hospitals in the north, which are facing risk of closure due lack of fuel, water, medical supplies, food, and the intense hostilities. Immediate efforts must be made to restore the functionality of Al-Shifa and all other hospitals to provide urgently needed health services in Gaza.
WHO reiterates its plea for collective efforts to bring an end to the hostilities and humanitarian catastrophe in Gaza. We call for an immediate ceasefire, the sustained flow of humanitarian assistance at scale, unhindered humanitarian access to all of those in need, the unconditional release of all hostages, and the cessation of attacks on health care and other vital infrastructure. The extreme suffering of the people of Gaza demands that we respond immediately and concretely with humanity and compassion.
The World Health Organization provides global leadership in public health within the United Nations system. Founded in 1948, WHO works with 194 Member States, across six regions and from more than 150 offices, to promote health, keep the world safe and serve the vulnerable. Our goal for 2019-2023 is to ensure that a billion more people have universal health coverage, to protect a billion more people from health emergencies, and provide a further billion people with better health and wellbeing.
Elecsys® HBeAg quant is an immunoassay for the in vitro qualitative and quantitative determination of hepatitis B e antigen (HBeAg) in human serum and plasma. In conjunction with other laboratory results and clinical information, HBeAg quantification may be used as an aid for the diagnosis and monitoring of patients with hepatitis B viral infection. Elecsys® HBeAg quant reports both a qualitative and a quantitative readout, providing greater value to clinicians and patients. The test can be used for samples from patients with unknown HBeAg status (first line testing) as well as those who have previously tested positive (second line testing). The immunoassay is intended for use on all available cobas e analysers.
HBV is a viral infection that attacks the liver and can cause both acute and chronic disease.1 It is the most common type of viral hepatitis affecting people of all ages, posing a significant burden on people and healthcare systems globally.1 In 2019, WHO estimated that 296 million people were living with chronic hepatitis B infection, with 1.5 million new infections each year. In this same year, hepatitis B resulted in an estimated 820,000 deaths, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer). The virus is most commonly transmitted from mother to child during birth and delivery, as well as through contact with blood or other body fluids during sex with an infected partner, unsafe injections or exposures to sharp instruments.1 While a vaccine exists to prevent HBV, there is currently no cure for patients who have been diagnosed with the infection.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan